Literature DB >> 7736408

Heterogeneity of cancer surveillance practices among medical oncologists in Washington and Oregon.

K E Richert-Boe1.   

Abstract

BACKGROUND: Medical oncologists provide long term care for patients who have been treated for cancer and are in remission. However, little is known about how physicians use routine laboratory and imaging tests for detecting cancer recurrence in their patients.
METHODS: To assess type and level of their surveillance testing of patients with cancer who are in remission, a cross-sectional survey of medical oncologists was performed. Seventy-three members of the American Society of Clinical Oncology residing in Washington and Oregon participated (70% response rate). Standardized questionnaires were mailed to medical oncologists using a multiple-mailing technique. Three scenarios, each describing a patient with cancer of the breast, colon, or prostate, were included. Participants were asked to indicate the frequency at which they would order seven different diagnostic tests in the routine follow-up of such patients.
RESULTS: Virtually all respondents would practice some level of follow-up testing of their patients. Although testing practices did not vary significantly according to physician age, year of graduation, practice type, or state of residence, there was considerable variability from physician to physician.
CONCLUSIONS: These results suggest that optimal cancer-surveillance testing programs for patients with cancer of the breast, colon, or prostate have not yet been satisfactorily defined.

Entities:  

Mesh:

Year:  1995        PMID: 7736408     DOI: 10.1002/1097-0142(19950515)75:10<2605::aid-cncr2820751031>3.0.co;2-#

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Costs and benefits of routine follow-up after curative treatment for endometrial cancer.

Authors:  O O Agboola; E Grunfeld; D Coyle; G A Perry
Journal:  CMAJ       Date:  1997-10-01       Impact factor: 8.262

2.  Routine follow up of breast cancer in primary care: randomised trial.

Authors:  E Grunfeld; D Mant; P Yudkin; R Adewuyi-Dalton; D Cole; J Stewart; R Fitzpatrick; M Vessey
Journal:  BMJ       Date:  1996-09-14

3.  Follow-up patterns of cancer survivors: a survey of Canadian radiation oncologists.

Authors:  Allison Y Ye; Winson Y Cheung; Karen J Goddard; Daniel Horvat; Robert A Olson
Journal:  J Cancer Surviv       Date:  2014-09-18       Impact factor: 4.442

4.  Preventive health care, 1999 update: 3. Follow-up after breast cancer. Canadian Task Force on Preventive Health Care.

Authors:  L K Temple; E E Wang; R S McLeod
Journal:  CMAJ       Date:  1999-10-19       Impact factor: 8.262

5.  Physicians' beliefs about breast cancer surveillance testing are consistent with test overuse.

Authors:  Paul K J Han; Carrie N Klabunde; Anne-Michelle Noone; Craig C Earle; John Z Ayanian; Patricia A Ganz; Katherine S Virgo; Arnold L Potosky
Journal:  Med Care       Date:  2013-04       Impact factor: 2.983

6.  Physician roles in the cancer-related follow-up care of cancer survivors.

Authors:  Carrie N Klabunde; Paul K J Han; Craig C Earle; Tenbroeck Smith; John Z Ayanian; Richard Lee; Anita Ambs; Julia H Rowland; Arnold L Potosky
Journal:  Fam Med       Date:  2013 Jul-Aug       Impact factor: 1.756

7.  Intensive follow-up strategies after radical surgery for nonmetastatic colorectal cancer: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Yaqin Zhao; Cheng Yi; Yu Zhang; Fang Fang; Andrew Faramand
Journal:  PLoS One       Date:  2019-07-30       Impact factor: 3.240

Review 8.  Intensive follow-up for women with breast cancer: review of clinical, economic and patient's preference domains through evidence to decision framework.

Authors:  Alessandra Lafranconi; Liisa Pylkkänen; Silvia Deandrea; Anke Bramesfeld; Donata Lerda; Luciana Neamțiu; Zuleika Saz-Parkinson; Margarita Posso; David Rigau; Ivan Sola; Pablo Alonso-Coello; Maria José Martinez-Zapata
Journal:  Health Qual Life Outcomes       Date:  2017-10-19       Impact factor: 3.186

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.